Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 9/20 | 0.37 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180939 | 0.88 | CHEK2 (0.37) | CHEK2AMY1AF7PARP1 | |
| SCHEMBL2183311 | 0.87 | CHEK2 (0.37) | CHEK2AMY1AF7PARP1HDAC6 | |
| SCHEMBL2185941 | 0.86 | CHEK2 (0.42) | CHEK2AMY1AF7PARP1MMP2 | |
| SCHEMBL2183895 | 0.85 | CHEK2 (0.36) | CHEK2AMY1AF7PARP1HDAC6 | |
| SCHEMBL2182007 | 0.85 | CHEK2 (0.41) | CHEK2AMY1AF7PARP1 | |
| SCHEMBL2182604 | 0.85 | CHEK2 (0.34) | CHEK2AMY1AF7PARP1MMP2 | |
| SCHEMBL2182129 | 0.85 | CHEK2 (0.34) | CHEK2AMY1AF7PARP1MMP2 | |
| SCHEMBL2184058 | 0.84 | CHEK2 (0.36) | CHEK2AMY1AF7 | |
| SCHEMBL2182399 | 0.84 | HSP90AA1 (0.42) | CHEK2AMY1APARP1CYP1A2CYP3A4 | |
| SCHEMBL2182589 | 0.84 | CHEK2 (0.34) | CHEK2AMY1AF7CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309721-B2 | HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof | SANOFI (FR) | 2012-11-13 | — | — | US | disclosed |
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | CHEK2 2483/4885AMY1A 3371/4885F7 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.